{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T18:32:20Z","timestamp":1780943540900,"version":"3.54.1"},"reference-count":11,"publisher":"Jaypee Brothers Medical Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.59556\/japi.74.1432","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:07:56Z","timestamp":1773292076000},"page":"45-47","source":"Crossref","is-referenced-by-count":1,"title":["Coexistent Antiphospholipid Syndrome with Polycythemia Vera in a 25-year-old Lady Presented with Splenic Vein Thrombosis"],"prefix":"10.59556","volume":"74","author":[{"given":"Mohammed Ameen","family":"C","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhargavan","family":"Pallivalappil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2914","reference":[{"issue":"(4):","key":"key20260312050753_B1","doi-asserted-by":"crossref","first-page":"409\u2013","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F JAK2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.","volume":"124","author":"Lussana","year":"2009;","journal-title":"Thromb Res"},{"issue":"(17):","key":"key20260312050753_B2","doi-asserted-by":"crossref","first-page":"1779\u2013","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005;","journal-title":"N Engl J Med"},{"issue":"(2):","key":"key20260312050753_B3","doi-asserted-by":"crossref","first-page":"295\u2013","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).","volume":"4","author":"Miyakis","year":"2006;","journal-title":"J Thromb Haemost"},{"issue":"(7):","key":"key20260312050753_B4","doi-asserted-by":"crossref","first-page":"530\u2013","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines.","volume":"12","author":"Asherson","year":"2003;","journal-title":"Lupus"},{"issue":"(4):","key":"key20260312050753_B5","doi-asserted-by":"crossref","first-page":"1019\u2013","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.","volume":"46","author":"Cervera","year":"2002;","journal-title":"Arthritis Rheum"},{"key":"key20260312050753_B6","doi-asserted-by":"crossref","first-page":"8432781.","DOI":"10.1155\/2018\/8432781","article-title":"Newer oral anticoagulants in the treatment of acute portal vein thrombosis in patients with and without cirrhosis.","volume":"2018:","author":"Priyanka","year":"2018;","journal-title":"Int J Hepatol"},{"issue":"(10):","key":"key20260312050753_B7","doi-asserted-by":"crossref","first-page":"2016\u2013","DOI":"10.1111\/jth.14261","article-title":"Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-\u03b22glycoprotein I antibody detection assays.","volume":"16","author":"Chayoua","year":"2018;","journal-title":"J Thromb Haemost"},{"issue":"(9):","key":"key20260312050753_B8","first-page":"1220\u2013","article-title":"Clinical relevance of isolated lupus anticoagulant positivity in patients with thrombotic antiphospholipid syndrome.","volume":"121","author":"Yin","year":"2021;","journal-title":"Thromb Haemost"},{"issue":"(10):","key":"key20260312050753_B9","doi-asserted-by":"crossref","first-page":"1296\u2013","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults.","volume":"78","author":"Tektonidou","year":"2019;","journal-title":"Ann Rheum Dis"},{"key":"key20260312050753_B10","doi-asserted-by":"crossref","first-page":"23247096221099893.","DOI":"10.1177\/23247096221099893","article-title":"Evaluation of apixaban in patients with antiphospholipid syndrome: a case series and review of literature.","volume":"10:","author":"Al Sulaiman","year":"2022;","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"(9):","key":"key20260312050753_B11","doi-asserted-by":"crossref","first-page":"1502\u2013","DOI":"10.1177\/09612033211021154","article-title":"Coexistent antiphospholipid syndrome and myeloproliferative neoplasm.","volume":"30","author":"Sayar","year":"2021;","journal-title":"Lupus"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:07:58Z","timestamp":1773292078000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-3-s1-45"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.59556\/japi.74.1432"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1432","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}